Crizotinib

Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition[1][2][3].

Product Specifications

CAS Number

[877399-52-5]

Product Name Alternative

PF-02341066

UNSPSC

12352005

Hazard Statement

H317, H319, H341, H400

Target

Anaplastic lymphoma kinase (ALK) ; c-Met/HGFR; Ligands for Target Protein for PROTAC; ROS Kinase

Type

Reference compound

Related Pathways

PROTAC; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Crizotinib.html

Purity

99.97

Solubility

DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic)

Smiles

ClC1=C(F)C=CC(Cl)=C1[C@H](OC2=CC(C3=CN(N=C3)C4CCNCC4)=CN=C2N)C

Molecular Formula

C21H22Cl2FN5O

Molecular Weight

450.34

Precautions

H317, H319, H341, H400

References & Citations

[1]Zou HY, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67 (9), 4408-4417.|[2]Christensen JG, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007, 6 (12 Pt 1), 3314-3322.|[3]Cui JJ, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) . J Med Chem. 2011 Sep 22;54 (18) :6342-63.|[4]Cullinane C, et al. Differential (18) F-FDG and 3'-deoxy-3'- (18) F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. J Nucl Med. 2011 Aug;52 (8) :1261-7|[5]Shen A, et al. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. Cancer Res. 2015 Nov 1;75 (21) :4548-59.|[6]Umapathy G, et al. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Sci Signal. 2014 Oct 28;7 (349) :ra102.|[7]Tucker ER, et al. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. Mol Oncol. 2017 Aug;11 (8) :996-1006.|[8]Liu H, et al. Identifying and Targeting Sporadic Oncogenic GeneticLiu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8 (3) :354-369.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

ACS Omega. 2023 Jun 14;8 (25) :22603-22612.|Arch Biochem Biophys. 2024 Mar:753:109905.|Biochim Biophys Acta Mol Cell Res. 2020 Jul;1867 (7) :118712.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biol Methods Protoc. 2025 Feb 13;10 (1) :bpaf012.|Biomark Res. 2024 Jan 25;12 (1) :13.|Biomed Chromatogr. 2019 Oct;33 (10) :e4611.|Biomed Chromatogr. 2024 Oct;38 (10) :e5986.|bioRxiv. 2024 Nov 6:2024.11.04.621884.|Blood Adv. 2023 Aug 8;7 (15) :4049-4063.|Blood Adv. 2025 Jul 2:bloodadvances.2024015322.|Blood. 2022 Feb 3;139 (5) :717-731. |Braz J Pharm Sci. 2015 Jun;51 (2) :2175-9790.|Cancer Discov. 2018 Mar;8 (3) :354-369.|Cancer Discov. 2023 Mar 1;13 (3) :598-615.|Cancer Discov. 2024 Sep 13:OF1-OF20.|Cancer Lett. 2018 May 28:422:19-28.|Cancer Med. 2020 Jun;9 (12) :4350-4359.|Cancer Res. 2015 Nov 1;75 (21) :4548-59. |Cancer Sci. 2025 Jul 23.|Cancers (Basel) . 2017 Oct 30;9 (11) . pii: E149. |Cancers (Basel) . 2024|Cell Rep Med. 2023 Feb 21;4 (2) :100911.|Cell Rep Med. 2024 Mar 19;5 (3) :101472.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Clin Transl Med. 2025 May;15 (5) :e70338. |Dis Model Mech. 2016 Sep 1;9 (9) :941-52.|Eberhard Karls Universität Tübingen. 2023 Sep 18.|EBioMedicine. 2023 Jan:87:104410.|Eur J Drug Metab Pharmacokinet. 2021 Sep;46 (5) :625-635.|Eur J Med Chem. 2017 Oct 20:139:674-697.|Evid Based Complement Alternat Med. 2019 Nov 7;2019:4253846.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|Front Oncol. 2020 May 12;10:696.|Fundam Clin Pharmacol. 2021 Oct;35 (5) :919-929.|Harvard Medical School LINCS LIBRARY|Int J Biol Macromol. 2025 Jun 4;318 (Pt 1) :144963.|Int J Mol Sci. 2022 Sep 17;23 (18) :10895.|Invest New Drugs. 2023 Apr;41 (2) :254-266.|J Cancer Res Clin Oncol. 2021 Jan;147 (1) :167-175.|J Exp Clin Cancer Res. 2022 Mar 29;41 (1) :113.|J Exp Clin Cancer Res. 2025 Jul 19;44 (1) :215.|J Med Chem. 2021 Mar 11;64 (5) :2725-2738.|J Med Chem. 2021 Oct 14;64 (19) :14344-14357.|J Med Chem. 2024 Oct 24;67 (20) :18098-18123.|J Pharm Anal. 2021 Dec;11 (6) :799-807.|J Solution Chem. 2014 Jul;43 (7) :1282-1295.|J Transl Med. 2023 Aug 5;21 (1) :530.|Leukemia. 2025 Aug 14.|Mol Cancer Ther. 2025 Jul 2;24 (7) :1005-1019.|Mol Oncol. 2017 Aug;11 (8) :996-1006.|Nat Biomed Eng. 2018 Aug;2 (8) :578-588.|Nat Commun. 2025 Jul 17;16 (1) :6587.|Oncogene. 2018 Mar;37 (11) :1417-1429.|Oncogene. 2024 Sep;43 (40) :2995-3002.|Oncotarget. 2014 May 15;5 (9) :2688-702.|Oncotarget. 2016 May 17;7 (20) :29011-22. |Oncotarget. 2019 Aug 13;10 (48) :4937-4950.|Patent. US20250269018A1.|PLoS One. 2021 Jun 8;16 (6) :e0252907.|PLoS One. 2025 Jan 21;20 (1) :e0308747.|PLoS One. 2019 Feb 11;14 (2) :e0212048. |Proteomes. 2023 Jun 2;11 (2) :20.|Research Square Preprint. 2022 Feb.|Research Square Print. 26 Oct, 2022|Research Square Print. September 14th, 2022.|Saudi Pharm J. 2015 Jan;23 (1) :75-84. |Sci Signal. 2014 Oct 28;7 (349) :ra102. |Sci Signal. 2015 Dec 8;8 (406) :ra125. |Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Sci Transl Med. 2021 Sep;13 (609) :eabb3738.|Signal Transduct Target Ther. 2024 Mar 9;9 (1) :65.|Spectrochim Acta A Mol Biomol Spectrosc. 2014 Oct 15;131:347-54.|Spectrochim Acta A Mol Biomol Spectrosc. 2021 Oct 5:259:119884.|Stem Cell Reports. 2017 Dec 12;9 (6) :1948-1960.|Talanta. 2019 Aug 15:201:217-225.|Technical University of Munich. 24.01.2018.|Transl Oncol. 2021 Jan;14 (1) :100887.|Transl Oncol. 2022 Jan;15 (1) :101272.|Int J Antimicrob Agents. 2025 Jun;65 (6) :107470.|J Hematol Oncol. 2018 Aug 29;11 (1) :109. |MedComm (2020) . 2025 Jul 21;6 (8) :e70286.